WW International Inc. reported fourth‑quarter 2025 results that exceeded analyst expectations on March 16, 2026. The company posted a GAAP loss of $0.58 per share, beating the consensus estimate of a $0.62 loss by 6.5 percent. Total revenue reached $162.8 million, outpacing the $149.1 million consensus estimate by roughly $13.7 million, a 9.2 percent beat.
The earnings beat was driven by a 32 percent year‑over‑year increase in clinical subscription revenue, which rose to $27 million and now accounts for 17 percent of total subscription revenue, up from 11 percent in the prior year. In contrast, the legacy behavioral segment saw a 12 percent decline in revenue, reflecting ongoing headwinds in that business line. The stronger clinical mix helped offset the revenue decline in the behavioral segment and contributed to the overall revenue beat.
Margin performance reflected a shift in the company’s cost structure. Adjusted EBITDA margin fell to 11.1 percent in Q4 2025 from 25.1 percent in Q4 2024, largely due to higher marketing spend associated with the company’s transition to a GLP‑1‑enabled model and the calendar‑year change in fiscal reporting. Despite the margin compression, the company’s operating income improved to $12.3 million from a $3.4 million loss in the same quarter a year earlier, driven by the clinical growth and disciplined cost management.
Management highlighted the strategic pivot toward integrated weight‑health services. CEO Tara Comonte noted that “our strategy is rooted in combining access to GLP‑1 medications with the behavioral support and community that have defined Weight Watchers for decades.” CFO Felicia DellaFortuna added that the fourth‑quarter results were “consistent with our strategic and financial objectives” and that the company exceeded its previously provided 2025 revenue and adjusted EBITDA guidance.
Looking ahead, WW International guided for fiscal 2026 revenue of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million, a slight upward revision from prior guidance. The guidance signals confidence in the continued growth of the clinical segment and the company’s ability to manage costs while expanding its integrated care model. The company’s successful Chapter 11 restructuring, which reduced debt by over 70 percent, further strengthens its balance sheet and positions it for long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.